Brian Vickery, MD, discusses a phase 1 trial evaluating the safety and tolerability of a microneedle stamp designed to deliver peanut protein through the skin.
News|Articles|February 4, 2025
FDA news in pediatrics: January 2025
Author(s)Patrick Campbell
A recap of the FDA submissions and regulatory decisions in pediatrics from January 2025.
Advertisement
Advertisement
Navigating the ever-evolving landscape of pediatric care means staying ahead of clinical developments, regulatory shifts, and therapeutic breakthroughs—each with the potential to reshape how we support children’s health. In the January 2025 FDA update from Contemporary Pediatrics, we highlight decisions that reflect both the complexity and promise of modern pediatrics, including new drug submissions, a pivotal ban on red No. 3 in food and ingested drugs, and an expanded clearance for a familiar face.
Related to this article
The FDA granted satralizumab priority review for MOGAD after phase 3 findings showed a 68% reduction in relapse risk versus placebo.
Amélie Lothe, PhD, discusses findings showing early, sustained benefits of fenfluramine treatment for patients with Lennox-Gastaut syndrome.
FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.
Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.
FDA approved apitegromab-mstn (Isembyld) for SMA in patients 2 years and up, based on phase 3 data showing added motor gains with SMN2 therapy.
A recap of the top FDA approvals, authorizations, and regulatory decisions affecting pediatric care during August 2026.
The FDA approved tiratricol (Emcitate) for peripheral thyrotoxicosis in MCT8 deficiency, the first approved therapy for the rare disorder.
Advertisement
Advertisement